Advice

following a resubmission:

mifamurtide (Mepact) is accepted for use within NHS Scotland.

Indication under review: in combination with post-operative multi-agent chemotherapy for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection, in children, adolescents and young adults. Safety and efficacy have been assessed in studies of patients 2 to 30 years of age at initial diagnosis.

Mifamurtide has been shown to increase overall survival compared with multi-agent chemotherapy alone in patients aged up to 30 years with newly-diagnosed resectable osteosarcoma.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of mifamurtide. This SMC advice is contingent upon the continuing availability of the PAS in NHS Scotland.

Download detailed advice146KB (PDF)

Download

Medicine details

Medicine name:
mifamurtide (Mepact)
SMC ID:
621/10
Indication:
For the treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults.
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Accepted
Date advice published
08 August 2011